Firefly Neuroscience Surges as Investors Appear to Cheer New Commercial Partnership Momentum

Firefly Neuroscience (AIFF) is up 32.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is investor enthusiasm around Firefly’s latest commercial-partnership activity tied to ADHD and broader brain-health adoption. While the exact trigger behind today’s spike is not fully confirmed, the move appears linked to a newly discussed NeuroSigma partnership and follows another strategic collaboration announced last week, reinforcing the view that Firefly is building distribution and clinical-use pathways for its FDA-cleared platform.

Details:

Firefly recently announced a strategic collaboration with Radial to integrate its FDA 510(k)-cleared, AI-powered Evoke platform into Radial’s clinical operating system across a growing brain-medicine network.

Firefly says its proprietary database now exceeds 200,000 EEG and ERP brain scans, a scale that can strengthen the commercial story around its precision-neuroscience tools.

NeuroSigma recently expanded commercialization efforts for Monarch eTNS, an FDA-cleared non-drug treatment for pediatric ADHD, which fits closely with Firefly’s focus on objective brain-function assessment in ADHD.

This could be because traders are betting that pairing diagnostic brain analytics with non-drug treatment access could improve Firefly’s market reach, even if financial terms or near-term revenue impact have not been detailed.

Sources:

GlobeNewswire, SEC, Firefly Neuroscience

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive AIFF Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$AIFF Hedge Fund Activity

We have seen 11 institutional investors add shares of $AIFF stock to their portfolio, and 14 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MURCHINSON LTD. added 650,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $786,500
BOOTHBAY FUND MANAGEMENT, LLC added 178,750 shares (+inf%) to their portfolio in Q2 2026, for an estimated $216,287
SCHONFELD STRATEGIC ADVISORS LLC removed 177,185 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $214,393
JANE STREET GROUP, LLC removed 112,392 shares (-62.4%) from their portfolio in Q2 2026, for an estimated $135,994
UBS GROUP AG removed 73,076 shares (-55.3%) from their portfolio in Q2 2026, for an estimated $88,421
SCIENTECH RESEARCH LLC removed 41,121 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $49,756
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 37,742 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $82,277

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.